Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Liquidia Technologies Inc (LQDA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 140,844
  • Shares Outstanding, K 15,632
  • Annual Sales, $ 2,710 K
  • Annual Income, $ -53,140 K
  • 60-Month Beta N/A
  • Price/Sales 51.74
  • Price/Cash Flow N/A
  • Price/Book 7.42

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.60
  • Number of Estimates 2
  • High Estimate -0.45
  • Low Estimate -0.74
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.33 +8.16%
on 04/18/19
17.00 -47.00%
on 03/19/19
-8.64 (-48.95%)
since 03/18/19
3-Month
8.33 +8.16%
on 04/18/19
20.05 -55.06%
on 03/01/19
-4.54 (-33.51%)
since 01/18/19

Most Recent Stories

More News
Analysis: Positioning to Benefit within Galmed Pharmaceuticals, Liquidia Technologies, Taylor Devices, Kingstone Companies, Aerpio Pharmaceuticals, and Pingtan Marine Enterprise -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Galmed Pharmaceuticals Ltd....

KINS : 13.68 (+0.51%)
LQDA : 9.01 (+0.56%)
PME : 2.30 (+0.88%)
GLMD : 8.00 (+0.13%)
ARPO : 0.98 (+1.36%)
TAYD : 11.85 (-0.13%)
Liquidia Technologies Presents Phase 3 Trial Data for LIQ861 at the ISHLT 39th Annual Meeting & Scientific Sessions

Liquidia Technologies, Inc. (Nasdaq: LQDA) ("Liquidia"), a late-stage clinical biopharmaceutical company focused on the development and commercialization of LIQ861, announced today additional detailed...

LQDA : 9.01 (+0.56%)
Liquidia Technologies to Present at Needham Healthcare Conference

Liquidia Technologies, Inc. (Nasdaq:LQDA) ("Liquidia"), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT(R)...

LQDA : 9.01 (+0.56%)
Liquidia Technologies Announces Closing of Offering of Common Stock

Liquidia Technologies, Inc. (Nasdaq:LQDA) ("Liquidia"), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT(R)...

LQDA : 9.01 (+0.56%)
Liquidia Technologies Announces Pricing of Offering of Common Stock

Liquidia Technologies, Inc. (Nasdaq:LQDA) ("Liquidia"), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT(R)...

LQDA : 9.01 (+0.56%)
Liquidia Technologies Announces Proposed Offering of Common Stock

Liquidia Technologies, Inc. (Nasdaq:LQDA) ("Liquidia"), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT(R)...

LQDA : 9.01 (+0.56%)
Liquidia's LIQ861 Meets Primary Endpoint in Pivotal Phase 3 INSPIRE Study in Patients with Pulmonary Arterial Hypertension

? LIQ861 was well-tolerated in PAH patients at two months of treatment

LQDA : 9.01 (+0.56%)
Liquidia Technologies Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update

-- Accepted by FDA into Emerging Technology Program to support review of PRINT(R) technology

LQDA : 9.01 (+0.56%)
Thinking about buying stock in Achieve Life Sciences, Kraft Heinz Co., Liquidia, Roku or Zillow?

InvestorsObserver issues critical PriceWatch Alerts for ACHV, KHC, LQDA, ROKU, and Z.

LQDA : 9.01 (+0.56%)
KHC : 32.96 (+0.21%)
Z : 36.28 (-1.89%)
ACHV : 3.54 (-1.12%)
Liquidia Technologies to Report 2018 Financial Results and Provide Corporate Update on February 26, 2019

Liquidia Technologies, Inc. (Nasdaq:LQDA) ("Liquidia"), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT(R)...

LQDA : 9.01 (+0.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade LQDA with:

Business Summary

Liquidia Technologies, Inc. is a late-stage clinical biopharmaceutical company. It focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. The company's product candidate consists of LIQ861 for the treatment of...

See More

Key Turning Points

2nd Resistance Point 9.46
1st Resistance Point 9.24
Last Price 9.01
1st Support Level 8.56
2nd Support Level 8.10

See More

52-Week High 38.46
Fibonacci 61.8% 26.95
Fibonacci 50% 23.40
Fibonacci 38.2% 19.84
Last Price 9.01
52-Week Low 8.33

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar